Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Connolly, Stuart J; Eikelboom, John W; Bosch, Jackie; Dagenais, Gilles; Dyal, Leanne; Lanas, Fernando; Metsarinne, Kaj; O'Donnell, Martin; Dans, Anthony L; Ha, Jong-Won; Parkhomenko, Alexandr N; Avezum, Alvaro; Lonn, Eva; Lisheng Liu; Torp-Pedersen, Christian; Widimsky, Petr; Maggioni, Aldo P; Felix, Camilo; Keltai, Katalin; Hori, Masatsugu; Yusoff, Khalid; Guzik, Tomasz J; Bhatt, Deepak L; Branch, Kelley R H; Bruns, Nancy Cook; Berkowitz, Scott D; Anand, Sonia S; Varigos, John D; Fox, Keith A A; Yusuf, Salim.
Lancet ; 391(10117): 205-218, 2018.
Artículo en Inglés | SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1064603

Documentos relacionados

  1. Does rivaroxaban have a role in treating patients with PAD?
  2. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
  3. Rivaroxaban in COMPASS trial.
  4. Reply.
  5. Long-term Renal Effects of Proton Pump Inhibitor Use.
  6. Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth.
  7. [Treatment of Patients with Stable Manifestations of Atherosclerotic Vascular Disease: New Possibilities (Conclusion of the Council of Experts from November 16, 2018, Rostov-on-Don)].
  8. What Is the Optimal Follow-up Time to Ascertain the Safety of Proton Pump Inhibitors?
  9. Reply.
  10. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.